



Drug Utilization Review Board Meeting Minutes November 12, 2024

DRAFT pending approval at the next meeting

DUR Board Members in attendance: Marin Broucek, M.D., Charlie Moore, R.P., Dave Randolph R.P.

Nebraska Medicaid & LTC attendees in person: Carisa Schweitzer-Masek, R.P. Deputy Director Population Health, Lee Stutzman, R.P., Pharmacy Director; Leah Spencer, R.N., Program Specialist; Dianne Garside, R.P., Spencer Moore, R.P.

Contracted attendees: Jamie Benson, R.P., Nebraska Total Care; Shannon Nelson, R.P., Molina Healthcare of Nebraska; Shaleigh Hammons, Account executive, Prime Therapeutics, Nikia Bennette-Carter, R.P. Pharmacist Prime Therapeutics

Public visitors in attendance in person: Randal Roth, Merck, Kurt Hendrickson, AbbVie, Jeff Houston, AbbVie, Donna Osterland, Sanofi, Shelly Nickerson, Neurocrine, Scott Bettis, Neurocrine

I. Opening and Introductions

The meeting was called to order at 6:30pm. The meeting was held at the Best Western Plus Lincoln Inn & Suites in Lincoln, NE. The open meetings act was available. Lee Stutzman R.P. was introduced as the new Pharmacy Director for Nebraska Medicaid.

II. Conflict of Interest or changes

No changes in conflict of interest were declared.

III. Agenda approval

The agenda was unanimously approved.

IV. Approval of Minutes from DUR Board, July 9, 2024 meeting

The minutes were unanimously approved.

V. Special Topics - None

VI. Retrospective DUR

A. Old Business –

a. SUPPORT ACT Review

- i. State provided data from previous state fiscal year on:
 1. Opioids with benzodiazepines
 2. Opioids with antipsychotics
 3. Opioids with gabapentin/pregabalin

b. ADHD medications and Antipsychotics in Foster Children

- i. Conversation regarding gaps in therapy due to shortages by board members
- ii. State will provide utilization data on ADHD medications at the next meeting

B. New Business – Randolph raises concerns regarding concomitant use of gabapentin and pregabalin. Randolph requests utilization data of these two drugs, excluding members undergoing a taper/switch.

VII. Prospective DUR

A. Old Business – None

B. New Business –

a. New Drug Review

State introduced three new drugs listed on the PDL: Iqirvo (elafibranor), Zoryve (roflumilast), and Ohtuvayre (ensifentrine). Their indications and criteria were discussed. All are placed on the PDL as non-preferred as they had not yet been reviewed by the P&T Committee.

b. Opioid Dependence Treatment Annual Review

State reviewed the current prior authorization form and the Informed Consent Form. No changes were recommended by the Board.

- i. Board mentioned that SUD treatments are potentially being underutilized. Options for provider education were discussed.

VIII. Future Meeting Date

The next meeting is scheduled for January 14, 2025.

IX. Concerns & Comments

A. Board Members:

- a. New Board member Matthew Titchener was introduced as he was a participant online
- b. Cost of dispensing survey was discussed.
- c. Charlie Moore raised concerns about the reimbursement

B. DUR Director and State Representatives: Cost of dispensing survey

C. Prime Therapeutics Representatives: None

D. Manage Care Organization (MCO) Representatives: None

X. Adjournment

The motion to adjourn the meeting was unanimously approved. Schweitzer-Masek adjourned the meeting at 7:50 p.m.